Interim Report January - September 2008 Tripep AB (publ)

Interim Report January - September 2008 Tripep AB (publ)

•	Research and development costs amounted to SEK 14.5 (13.3) m
•	The loss after tax was SEK -23.5 (-21.7) m
•	Earnings per share were SEK -3.16 (-3,99)
•	The company had no net sales for the period
•	The company carried out a rights issue during the third quarter 2008 which
raised approx. SEK 3.4 m before transaction costs
•	Patent application filed for a new antibiotic-free formulation of ChronSeal®
in collaboration with Kringle Pharma, Inc. 
•	New application filed with the Swedish Medical Products Agency for a phase II
trial on ChronSeal®
•	Tripep secured a first US patent on a new type of immunotherapy against HIV-1

Events after the end of the reporting period
•	Tripep has obtained an approval from the Norwegian Medical Products Agency to
start the phase II study with ChronSeal
•	Tripep carries out new issues of shares of in total SEK 9.9 m
•	Tripep secures financing in ChronSeal
•	The first nine patients in the ChronVac-C® study have concluded the treatment
and shows positive efficacy data i.e activation of immune responses and lowering
of viral levels in the blood without any unexpected or serious side effects
being reported


For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se




About Tripep
Tripep AB is a Swedish biotechnology research company that develops and
commercialises candidate drugs based on patented technologies. Tripep is
focusing on the following research projects; wound healing therapy ChronSeal®
and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS®
technology platform. The Tripep share is admitted to trade on First North.
Remium AB is Certified Adviser for Tripep AB.  For more information, please
refer to the company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take